- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06913023
Semaglutid zur Verhinderung von Diabetes mellitus nach der Transplantation (SPOT-DM)
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Cheng Xu
- Telefonnummer: 8508 416-340-4800
- E-Mail: cheng.xu@uhn.ca
Studienorte
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 1Y6
- St. Paul's Hospital
-
Kontakt:
- Vikas S Srinivasan, MD PhD FRCPC
- Telefonnummer: 604-806-8970
- E-Mail: vikas.sridhar@phc.ca
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2N2
- Toronto General Hospital
-
Kontakt:
- Cheng Xu
- Telefonnummer: 8508 416-340-4800
- E-Mail: cheng.xu@uhn.ca
-
Hauptermittler:
- Sunita Singh, MD MSc FRCPC
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Signed and dated written informed consent.
-
Adult (≥18 years) recipients of a living or deceased donor kidney transplant
-
Between 4- and 12-weeks post kidney transplant
-
Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)
-
At risk for PTDM at the time of transplant based on the following criteria:
- BMI ≥ 25 kg/m2, or
- Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
- 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
- HbA1C 5.5-6.4% (at risk for DM or prediabetes).
Exclusion Criteria:
- Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
- Kidney-Pancreas transplant recipient
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2B
- Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
- Use of GLP1RA in the 30 days prior to screening
- Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
- With known or suspected hypersensitivity to semaglutide or related products
- Patient not able to understand and comply with study requirements, based on Investigator's judgment.
- Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
- History of glucose-galactose malabsorption syndrome
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Semaglutide
Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant. |
Subcutaneous semaglutide 0.25mg for 4 weeks. Subcutaneous semaglutide 0.5mg for 4 weeks. Subcutaneous semaglutide 1.0 mg for 4 weeks. Subcutaneous semaglutide 1.7 mg for 4 weeks Subcutaneous semaglutide 2.4 mg for 8 weeks |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
2-hour OGTT
Zeitfenster: 24 weeks
|
The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies. |
24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Systolischer Blutdruck
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Veränderung des Körpergewichts
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Änderung des Taillenumfangs
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Veränderung des HbA1c
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Veränderung des Fastenblutglukoses
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Änderung des Seruminsulins
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Änderung des Fasten -Lipidprofils
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Diastolischer Blutdruck
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Mittlerer arterieller Druck
Zeitfenster: 24 Wochen
|
24 Wochen
|
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Zeitfenster: 24 weeks
|
: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur. |
24 weeks
|
|
Estimated GFR
Zeitfenster: 24 weeks
|
Calculated by CKD-EPI 2021 equation |
24 weeks
|
|
GFR
Zeitfenster: 24 weeks
|
Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
24 weeks
|
|
Albuminuria
Zeitfenster: 24 weeks
|
measuring urine albumin excretion from a 24-hour urine collection |
24 weeks
|
|
Natriuresis
Zeitfenster: 24 weeks
|
Assessed with a 24-hour urine collection for sodium excretion |
24 weeks
|
|
Percentage of body fat
Zeitfenster: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
|
Change in liver enzymes
Zeitfenster: 24 weeks
|
ALT and AST |
24 weeks
|
|
Change in fibrosis level
Zeitfenster: 24 weeks
|
Transient elastography |
24 weeks
|
|
Change in steatosis level
Zeitfenster: 24 weeks
|
Transient elastography |
24 weeks
|
|
Percentage of extracellular fluid
Zeitfenster: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in kidney oxygenation (R2*)
Zeitfenster: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney fibrosis (ADC)
Zeitfenster: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney perfusion
Zeitfenster: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney volume
Zeitfenster: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney inflammation (T1)
Zeitfenster: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 25-5093
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .